You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR OZURDEX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OZURDEX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00450801 ↗ R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma Completed University of Miami Phase 2 2004-04-01 RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy followed by thalidomide works in treating patients with previously untreated mantle cell lymphoma.
NCT01027650 ↗ Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO) Completed Allergan Phase 1/Phase 2 2010-03-01 This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion. This study is being conducted in two stages: Stage 1 will enroll approximately 21 subjects who will receive a single open label intravitreal injection of either 75 ug, 300 ug, 600 ug or 900 ug of AGN208397 and be followed for 12 months post treatment; based on Stage 1 results, Stage 2 will enroll approximately 96 subjects who will receive a single masked intravitreal injection of one of three doses of AGN208397 or Ozurdex® and be followed for 12 months post treatment.
NCT01122511 ↗ Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration Terminated Allergan Phase 2 2010-08-01 This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OZURDEX

Condition Name

Condition Name for OZURDEX
Intervention Trials
Macular Edema 30
Diabetic Macular Edema 29
Retinal Vein Occlusion 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OZURDEX
Intervention Trials
Macular Edema 64
Edema 50
Retinal Vein Occlusion 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OZURDEX

Trials by Country

Trials by Country for OZURDEX
Location Trials
United States 133
Australia 16
Canada 8
France 8
Spain 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OZURDEX
Location Trials
California 14
Texas 11
Florida 11
Maryland 9
Massachusetts 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OZURDEX

Clinical Trial Phase

Clinical Trial Phase for OZURDEX
Clinical Trial Phase Trials
Phase 4 27
Phase 3 6
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OZURDEX
Clinical Trial Phase Trials
Completed 46
Recruiting 14
Terminated 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OZURDEX

Sponsor Name

Sponsor Name for OZURDEX
Sponsor Trials
Allergan 42
Johns Hopkins University 4
Postgraduate Institute of Medical Education and Research 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OZURDEX
Sponsor Trials
Other 94
Industry 62
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.